Moderate Cross-Pillar

PDE5 Inhibitors (Viagra, Cialis): Solid for a Few Uses, Promising for Longevity, Not Yet Proven

Summary

Sildenafil (Viagra), tadalafil (Cialis) and their relatives are genuinely effective and generally well-tolerated for their established jobs — erectile dysfunction, the lower-urinary-tract symptoms of an enlarged prostate (daily low-dose tadalafil), and pulmonary arterial hypertension — and the recent observational signals that regular users have lower mortality, fewer cardiovascular events and less dementia are biologically plausible through the nitric-oxide/cGMP vasodilatory pathway; but every one of those longevity and brain claims is observational, heavily confounded by healthy-user and ind

Why Moderate

Moderate Evidence is the entry-level tier because the entry's centre of gravity — the "is it safe, what else is it for, does it help you live longer" question the reader is actually asking — is a mixture of firmly established fact and genuinely unproven association, and the tier reflects the whole, not the strongest slice.

Why not Strong overall: although several individual claims are Strong (see the split below), the headline the entry is built to answer — the longevity/cardiovascular/dementia story — is observational, confounded and partly contradicted, with no RCT. Letting the established-use strength set the whole-entry tier would misrepresent the protective claims that the reader is most tempted to over-read.

Why not Emerging overall: the established uses (ED, BPH/LUTS, PAH) and the load-bearing safety facts (nitrate contraindication, NAION label warning) are Strong, regulatory- and RCT-backed. Pinning the whole entry at Emerging would under-rate the settled core and, worse, under-weight a lethal contraindication.

The per-claim split (read this, not just the headline):
• Erectile dysfunction, BPH/LUTS (daily tadalafil), PAH functional benefit: Strong (RCT- and label-backed).
• Nitrate contraindication: Strong (regulatory label, settled pharmacology).
• NAION vision-loss risk: Emerging/Moderate (rare, label-acknowledged, causality debated).
• Longevity / cardiovascular-protection / dementia-prevention associations: Emerging (observational, confounded, partly contradicted, no RCT).

Practical takeaway

The framing to hold: these are effective, generally well-tolerated drugs for a few established jobs, and an interesting but unproven hypothesis for everything beyond them. Any decision to start, switch or stop one is a shared decision with a clinician who knows your heart, your medications and your eyes — nothing here is a recommendation to self-dose.

For the established uses, the evidence supports the drug.
• Erectile dysfunction: first-line pharmacotherapy with high response rates. Lifestyle levers (which matter and are often the root cause) are owned by erectile_dysfunction_lifestyle; this entry only notes that the drug itself is well-established.
• Lower-urinary-tract symptoms of an enlarged prostate: daily low-dose tadalafil is an approved, RCT-backed option — worth raising with a clinician if BPH symptoms are the issue. Lifestyle management is owned by bph_prostate_lifestyle.
• Pulmonary arterial hypertension: a specialist-managed use where sildenafil improves function and slows worsening (but does not extend life) — not a self-directed decision in any sense.

For the longevity, heart and brain claims, treat it as a hypothesis, not a reason to start.
• The lower-mortality, fewer-cardiovascular-events and less-dementia associations are real associations but observational and heavily confounded. "Healthier men take the drug" is a sufficient alternative explanation for much of the signal.
• There is no randomised trial showing a longevity or dementia benefit, and the best-controlled analyses (the DREAM cohort, Mendelian randomisation) did not find the dementia effect. Starting the drug for these outcomes is running ahead of the evidence.
• If you are already taking a PDE5 inhibitor for an established reason, none of this is a cause for alarm — it simply means the protective story is a bonus hypothesis, not a demonstrated fact you can bank on.

The two safety facts that are not negotiable.
• Never combine with nitrates — in any form. If you take nitrate medication for angina or heart disease, or use "poppers" (amyl nitrite) recreationally, a PDE5 inhibitor can drop your blood pressure to a fatal degree. This is the one absolute rule.
• Sudden vision loss in one eye is an emergency. Stop the drug and seek urgent care. The risk (NAION) is rare but can be permanent, and is higher if you have diabetes, high blood pressure, or are over 50.

Also flag to a clinician before starting:
• Alpha-blockers (often prescribed for BPH or blood pressure) can combine with PDE5 inhibitors to cause symptomatic low blood pressure — dose separation and medical supervision matter.
• Severe cardiovascular disease, a recent heart attack or stroke, or significantly low baseline blood pressure warrant caution.
• Potent CYP3A4 inhibitors (for example ritonavir, ketoconazole) raise drug levels and require dose adjustment.

Evidence detail

Why This Entry Exists

The public conversation about PDE5 inhibitors has split into two exaggerations at once. On one side is the shrinking of the drug class to a single punchline — "the sex pill" — which hides that these are versatile vasodilators with three solidly established uses and a couple of reasonable off-label ones. On the other side is a newer and more seductive overreach: a run of large database studies has reported that men who take these drugs die less, have fewer heart attacks and strokes, and get less Alzheimer's, and this has been repackaged by longevity influencers and telehealth vendors into "Viagra is an anti-aging drug." Both framings mislead. The first undersells a genuinely useful medicine; the second oversells a hypothesis as if it were a result.

So this entry holds the honest middle. For the established uses the evidence is strong and the drugs work — that part is settled and RCT-backed. Beyond that, the longevity, cardiovascular-protection and dementia-prevention story is a promising association, not a demonstrated effect. The men who get prescribed these drugs are, on average, healthier, more sexually active and more engaged with healthcare than those who do not — every one of those traits independently predicts lower dementia and lower mortality, which is exactly the confounding that inflates the apparent benefit. At least one carefully controlled cohort and the drug-target genetics found no Alzheimer's benefit, and no trial has tested a longevity or dementia endpoint. The message a curious reader needs is: the drugs are good at what they are proven to do, the protective story is interesting but unproven, and there are two safety facts you do not get to be casual about.

This is a pharmacological topic, so the posture throughout is evidence and shared decision-making, not prescription. Starting, switching or stopping any of these drugs is a decision to make with a clinician who knows your heart, your other medications and your eyes.

What bad advice this protects against, in all directions:
• "It's just a sex pill, nothing else." → PDE5 inhibitors are established treatment for benign-prostate urinary symptoms (daily tadalafil) and pulmonary arterial hypertension, and are used off-label for Raynaud's and altitude sickness — the ED headline hides a whole drug class.
• "Viagra is a proven longevity and anti-Alzheimer's drug — everyone should take it." → every supporting study is observational and confounded; a well-controlled cohort and Mendelian-randomisation found no dementia benefit; no randomised trial shows any longevity or dementia effect.
• "It's basically risk-free, buy it online and self-dose." → the nitrate interaction can be fatal, there is a rare permanent-vision-loss risk (NAION), and alpha-blocker and severe-heart-disease interactions are real — this is a prescription decision, not a supplement.
• "Poppers plus a blue pill is fine." → amyl nitrite ("poppers") is a nitrate; combining it with any PDE5 inhibitor is the exact contraindicated interaction that drops blood pressure catastrophically.
• "The mortality benefit is causal because the biology makes sense." → biological plausibility is not proof; the same vasodilatory logic sits on top of severe healthy-user and confounding-by-indication bias, which is why the association is emerging, not established.
• "There's no downside to trying it for the brain benefits." → off-label self-dosing on the strength of a confounded association is exactly the narrative overreach this entry exists to correct.

This entry owns the is-it-safe / other-uses / longevity question for the PDE5 class as a drug class. It defers ED lifestyle management to erectile_dysfunction_lifestyle and the lifestyle management of an enlarged prostate to bph_prostate_lifestyle, and it routes there rather than re-arguing them.

Evidence

Organised as established uses first, then the emerging protective claims, then the methodology that keeps those claims where they are. The tier signal is inline — read it, because the established and emerging halves of this entry sit two tiers apart.

The established uses are Strong Evidence — proven, guideline- and label-backed.

1. Erectile dysfunction — the flagship, high response rates (Strong Evidence). PDE5 inhibitors have been first-line pharmacotherapy for erectile dysfunction since sildenafil's US approval in 1998, with consistently high response rates across the class and decades of post-marketing use. This is the least contested claim in the entry. (FDA sildenafil/Viagra prescribing information, US approval 1998. Strong Evidence — regulatory-label and long-established clinical use. Original trials were manufacturer-sponsored (Pfizer), but efficacy has been reproduced independently for a quarter-century.)

2. Benign prostatic hyperplasia / lower-urinary-tract symptoms — daily low-dose tadalafil (Strong Evidence). Tadalafil 5 mg once daily was FDA-approved in 2011 for the lower-urinary-tract symptoms of benign prostatic hyperplasia, and a meta-analysis of thirteen studies (fifteen randomised comparisons) confirmed efficacy for those symptoms with good tolerability. This is a genuinely separate, established indication, not an ED spillover. (FDA Cialis label; tadalafil BPH/LUTS meta-analysis, Frontiers in Medicine 2021, PMC8545998. Strong Evidence — RCT-backed and label-approved. Industry-originated (Lilly) but replicated in independent meta-analysis. Lifestyle management of BPH is owned by bph_prostate_lifestyle.)

3. Pulmonary arterial hypertension — sildenafil as Revatio (Strong Evidence, with a limit). In pulmonary arterial hypertension, sildenafil (branded Revatio) improves exercise capacity — roughly a 31-metre gain in six-minute walk distance — and reduces clinical worsening (relative risk about 0.39, 95% CI 0.21–0.69) in a systematic review of four trials totalling 545 patients. The honest limit: it improves function and slows deterioration but does not improve all-cause mortality, and that distinction matters. (Sildenafil PAH systematic review, Respiratory Medicine 2014, 4 trials, 545 patients. Strong Evidence for the functional endpoints; explicitly no mortality benefit. Raynaud's phenomenon and altitude sickness are plausible off-label uses — Raynaud's vasodilatory rationale is covered in raynauds_phenomenon_evidence.)

The protective/longevity claims are Emerging — observational, biologically plausible, and confounded.

4. Observational mortality and cardiovascular association (Emerging). In a TriNetX cohort of roughly 509,788 US men with erectile dysfunction (drawn from about 50 million records), tadalafil and sildenafil use was associated over three-year follow-up with reduced all-cause mortality (relative risk about 0.66 and 0.76 respectively), fewer myocardial infarctions (0.73 / 0.83), fewer strokes (0.66 / 0.78), less venous thromboembolism (0.79 / 0.80) and less dementia (0.68 / 0.75), with tadalafil showing the larger effects. A separate claims-based cohort linked tadalafil to lower major adverse cardiovascular events (hazard ratio about 0.81) and lower all-cause death (hazard ratio about 0.56). Biologically plausible through vasodilation — but observational, with no randomised trial. (Jehle et al., "Benefits of Tadalafil and Sildenafil on Mortality, CVD and Dementia," Am J Med 2024, PMID 39532245; tadalafil MACE cohort, PMC10878497. Emerging — large but observational, database/academic, healthy-user bias inflates the apparent benefit.)

5. The Alzheimer's/dementia signal is genuinely mixed (Emerging, directly conflicting). Supportive: Adesuyan et al. (Neurology 2024) found PDE5-inhibitor initiation associated with about 18% lower Alzheimer's risk (hazard ratio around 0.82) in men with erectile dysfunction, and a five-study meta-analysis of 885,380 patients reported a hazard ratio of 0.47 (95% CI 0.27–0.82). Contradictory: the DREAM study — a well-controlled pulmonary-hypertension cohort adjusting for 76 confounders — found no reduction in all-cause dementia across four separate analytic approaches, and drug-target Mendelian-randomisation results are inconsistent. The net position is promising, not established, precisely because the best-controlled analyses disagree with the raw associations. (Adesuyan et al., Neurology 2024, WNL.0000000000209131; meta-analysis, Aging-US 2024, PMC11984433; negative DREAM study, PMC9598543, PMID 36330433; Mendelian-randomisation study, medRxiv 2024.02.15.24302874. Emerging — directly conflicting evidence, no RCT. Alzheimer's drug-repurposing interest and publication bias favour positive signals.)

6. The confounding critique is explicit in the literature (why the emerging claims stay emerging). The methodological problem is stated openly by the authors themselves: men prescribed PDE5 inhibitors are typically healthier, more sexually active and more engaged with healthcare — traits independently associated with lower dementia and mortality, i.e. healthy-user bias stacked on confounding-by-indication. Because use is "as-needed" and influenced by health status, and because dementia has a long prodrome, protopathic and reverse-causation bias are also live. The authors uniformly call for randomised trials before any clinical translation, and no longevity or dementia RCT exists. (Methodological discussion across npj Dementia 2025, s44400-025-00005-3; World Journal of Men's Health, wjmh.250313; and the Mendelian-randomisation discussion, medRxiv 2024.02.15.24302874. Methodological — the reason the protective claims cannot yet be called causal. See healthy_user_bias and publication_bias_and_evidence_distortion.)

The load-bearing safety facts are Strong Evidence — regulatory and settled.

7. Nitrate co-administration is an absolute contraindication (Strong Evidence, load-bearing). Because both nitrates and PDE5 inhibitors amplify the nitric-oxide/cGMP pathway, giving them together can precipitate life-threatening, sometimes fatal hypotension. Sildenafil and all PDE5 inhibitors are contraindicated with organic nitrates and nitric-oxide donors in any form — including recreational "poppers" (amyl nitrite). This is the single most important safety fact in the entry. (FDA sildenafil/Viagra prescribing information, Contraindications section; DailyMed labels; US approval 1998. Strong Evidence — manufacturer label mandated by FDA, with no incentive to overstate a contraindication.)

8. NAION — rare sudden vision loss, a real but uncommon signal (Emerging/Moderate, label-acknowledged). Non-arteritic anterior ischemic optic neuropathy, a rare and sometimes permanent loss of vision (usually in one eye), carries an FDA class label warning added in 2007 after review of 43 post-marketing cases. The estimated incidence is around 2.8 cases per 100,000 patient-years of sildenafil exposure, and most affected patients had pre-existing vascular or anatomic risk factors — a "crowded" optic disc, age over 50, diabetes, hypertension. Real, rare, causality still debated, but label-acknowledged and worth knowing. (FDA PDE5-inhibitor labels, 2007 class warning; NAION incidence estimate about 2.8/100,000 patient-years; literature review, PMC9437418. Emerging/Moderate — rare, causality debated. The incidence estimate draws partly on manufacturer trial and epidemiologic data, so it may understate.)

Mechanism

Why one drug class does so many jobs. PDE5 inhibitors block phosphodiesterase type 5, the enzyme that breaks down cyclic GMP (cGMP). Nitric oxide raises cGMP, cGMP relaxes vascular smooth muscle, and PDE5 normally clears cGMP to end that relaxation. Inhibit PDE5 and cGMP persists, so nitric-oxide-driven vasodilation is amplified and prolonged. That single mechanism explains the whole clinical range: more blood flow into penile tissue (erectile dysfunction), relaxation of prostate and bladder-neck smooth muscle (lower-urinary-tract symptoms), and dilation of the pulmonary vasculature (pulmonary arterial hypertension), with the same logic underlying the off-label use in Raynaud's and altitude sickness.

Why the same mechanism makes the longevity story plausible — but only plausible. If the drug's job is to enhance nitric-oxide/cGMP vasodilation, then chronic use might, in principle, improve endothelial function, perfusion and vascular health across many organs, including the brain. That is a coherent hypothesis and it is exactly why the observational mortality, cardiovascular and dementia associations do not look absurd. But plausibility is upstream of proof. A believable mechanism tells you a benefit could exist; it does not tell you the association you observe is that benefit rather than the shadow of who gets prescribed the drug.

Why the nitrate interaction is the same mechanism turned lethal. Nitrates (for angina) and recreational nitrites both donate nitric oxide, driving cGMP up; PDE5 inhibitors stop cGMP being cleared. Stack the two and you get an uncontrolled, additive vasodilation — blood pressure can fall far enough to be fatal. This is not an idiosyncratic reaction or an allergy; it is the drug's own pharmacology with the brakes removed, which is why it is an absolute contraindication rather than a cautious "monitor closely."

Why NAION is a perfusion event. The optic nerve head has a delicate blood supply, and NAION is thought to arise when perfusion to it drops. Whether PDE5-inhibitor-driven vascular changes contribute causally is still debated, but the affected patients cluster around pre-existing vascular vulnerability (a crowded disc, diabetes, hypertension, age over 50), which fits a perfusion mechanism and explains why the absolute risk is low but concentrated in vascularly susceptible eyes.

Risks And Contraindications

• The nitrate contraindication is the load-bearing safety fact — put it first and never soften it. Co-administering any PDE5 inhibitor with organic nitrates or nitric-oxide donors can cause life-threatening or fatal hypotension. This is an absolute contraindication. It applies to anyone using nitrate medication for angina or heart disease, and to recreational "poppers" (amyl nitrite). No framing, off-label use or longevity rationale overrides it.
• NAION — rare but sometimes permanent vision loss. Sudden loss of vision, usually in one eye, is a recognised label-warned risk. It is uncommon (around 2.8 cases per 100,000 patient-years) and concentrated in people with vascular or anatomic risk factors (crowded optic disc, age over 50, diabetes, hypertension), but the outcome can be permanent. The rule for the reader is simple: sudden monocular vision loss means stop and seek care immediately.
• Alpha-blocker interaction. Because alpha-blockers (common for BPH and hypertension) and PDE5 inhibitors both lower blood pressure, combining them can cause symptomatic hypotension. Dose separation and medical supervision are needed — this is a "with a clinician" situation, not a self-managed one.
• Cardiovascular and drug-interaction cautions. Use caution with severe cardiovascular disease, recent myocardial infarction or stroke, and significant baseline hypotension. Potent CYP3A4 inhibitors (ritonavir, ketoconazole and others) increase PDE5-inhibitor levels and require dose adjustment.
• The dominant non-safety risk is narrative overreach. Framing PDE5 inhibitors as a proven longevity or anti-dementia drug — when no randomised trial supports it and the best-controlled analyses disagree — risks driving off-label self-dosing on the strength of a confounded association. Do not present the mortality or Alzheimer's associations as causal. The honest line is "promising hypothesis, unproven," and the clinical decision belongs with a clinician, not a longevity headline.
• Shared-decision boundary. This entry is evidence, not medical advice. Starting, changing or stopping any of these drugs — especially against a backdrop of heart disease, other medications, or eye risk factors — is a decision to make with a clinician who has the full picture.

Controversy

Nature: a genuinely effective, well-tolerated drug class with solid established uses, wrapped in a newer and much shakier longevity/brain story — with error at both poles: underselling the class as "just a sex pill" on one side, and overselling a confounded association as a proven anti-aging effect on the other.

Position A — "PDE5 inhibitors are effective, safe enough, and the protective signals are real and consistent."
• Best evidence: the established uses are RCT- and label-backed (ED, BPH/LUTS with daily tadalafil, PAH with sildenafil), the drugs are generally well-tolerated, and the observational protective signals (lower mortality, fewer cardiovascular events, less dementia) are large, directionally consistent across several database cohorts, and biologically plausible through the nitric-oxide/cGMP pathway.
• Where it goes wrong if overstated: it slides into "Viagra is a proven longevity and anti-Alzheimer's drug, so take it for that," treating association as causation and biological plausibility as proof.

Position B — "The longevity and dementia claims are unproven, confounded, and partly contradicted; and the drug is not risk-free."
• Best evidence: every supporting study is observational and vulnerable to healthy-user bias, confounding-by-indication and protopathic/reverse-causation bias; the well-controlled DREAM cohort (76 confounders) and Mendelian-randomisation work found no dementia benefit; no RCT has tested a longevity or dementia endpoint; and the nitrate contraindication and NAION signal mean the class carries real, occasionally severe, risk.
• Where it goes wrong if overstated: it can tip into dismissing the drug's genuinely established and valuable uses, or treating the protective hypothesis as disproven rather than merely unproven — the associations are real, they are just not yet shown to be causal.

The funding/bias dimension — cui bono, both ways. The founding efficacy trials (ED, PAH, BPH) were manufacturer-sponsored — Pfizer for sildenafil (Viagra/Revatio), Lilly for tadalafil (Cialis) — but the established-use efficacy has since been reproduced in independent meta-analyses, so that bias is largely washed out. The longevity/cardiovascular/dementia literature is different in an instructive way: it is mostly academic and database-driven (TriNetX, claims data, EHR cohorts) with no obvious direct pharma funding, which cuts against a simple "drug-company hype" reading. But two other incentives push the protective story: Alzheimer's drug-repurposing programs and publication bias favour positive signals, and telehealth ED vendors and longevity/biohacker influencers benefit commercially from reframing a cheap, off-patent generic as an anti-aging drug. Cui bono the other way: essentially no one profits from emphasising the confounding, which is why the sober methodological critiques (DREAM, the Mendelian-randomisation nulls) get far less airtime than "Viagra cuts Alzheimer's risk" headlines.

Realised Position: For the established uses these drugs work and are well-tolerated — that part is settled, and the entry says so plainly. Beyond that, treat the longevity, heart and brain story as a promising hypothesis, not a reason to start the drug: the associations are real but observational and heavily confounded, and no trial proves benefit. Two safety facts are load-bearing and non-negotiable — never combine with nitrates (fatal blood-pressure drop, poppers included), and treat sudden vision loss in one eye as an emergency — and alpha-blocker and severe-cardiac situations need a clinician. The honest headline is: proven for a few things, promising for longevity, not yet proven, and not a self-dosing decision.

Cross-Pillar Connections

This is a genuinely cross-pillar topic — one vasodilator drug class touches sexual function, urinary/prostate health, pulmonary and cardiovascular medicine, and (speculatively) cognitive longevity.
• Cross-pillar (erectile_dysfunction_lifestyle): owns the lifestyle root causes and management of erectile dysfunction; this entry holds only that PDE5 inhibitors are established first-line pharmacotherapy and defers the lifestyle levers there.
• Cross-pillar (bph_prostate_lifestyle): owns the lifestyle management of an enlarged prostate; this entry holds only that daily low-dose tadalafil is an established drug option for BPH/LUTS.
• Conditions (cardiovascular_health_management): the cardiovascular context — nitrate use for angina (the fatal-interaction population), severe-heart-disease cautions, and the vascular endpoints the emerging associations are built on.
• Conditions (raynauds_phenomenon_evidence): the vasodilatory rationale behind the off-label Raynaud's use, where the same nitric-oxide/cGMP mechanism applies.
• Evidence method (healthy_user_bias): the core reason the longevity/dementia associations stay emerging — healthier men get prescribed the drug, inflating the apparent benefit.
• Evidence method (publication_bias_and_evidence_distortion): why positive "Viagra protects the brain" signals get more airtime than the well-controlled nulls (DREAM, Mendelian randomisation).

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd upgrade the longevity/protective claims from emerging toward established if a randomised controlled trial (for instance a phase III PDE5-inhibitor-for-Alzheimer's-prevention trial) showed a genuine reduction in incident dementia, or in a hard cardiovascular or mortality endpoint, versus placebo.
• We'd also upgrade if confounding-robust evidence converged on causation — multiple concordant Mendelian-randomisation analyses plus target-trial-emulation cohorts using active comparators and negative-control outcomes — rather than the raw observational associations we have now.
• We'd soften the established-use tier only if post-marketing safety data materially raised the NAION rate or the cardiovascular event rate for these drugs.
• What would NOT move us: the nitrate contraindication is settled pharmacology and no plausible finding overturns it; and biological plausibility alone, however elegant, will not be allowed to stand in for a missing trial.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs in several directions here, and the pattern is unusually informative.
• The established-use efficacy is largely conflict-washed. The founding ED, PAH and BPH trials were manufacturer-sponsored (Pfizer for sildenafil, Lilly for tadalafil), which is the classic bias flag — but those efficacy claims have since been reproduced in independent meta-analyses, so the original sponsorship no longer carries the weight it would for an unreplicated finding.
• The longevity literature does not fit a simple pharma-hype read. The mortality, cardiovascular and dementia associations come mostly from academic and database work (TriNetX, claims data, EHR cohorts) with no obvious direct drug-company funding. These are off-patent generics; the manufacturers have little to gain from promoting an anti-aging story for a cheap pill they no longer hold exclusivity on.
• But other incentives push the protective story hard. Alzheimer's drug-repurposing programs and ordinary publication bias favour positive signals over nulls, so "Viagra cuts Alzheimer's risk" is more publishable and more shareable than "well-controlled cohort finds no effect." And telehealth ED vendors and longevity/biohacker influencers benefit commercially from reframing a cheap generic as an anti-aging drug — a direct financial reason to over-hype.
• Almost no one profits from the sober correction. The methodologically strongest counterweights — the DREAM cohort's null, the Mendelian-randomisation inconsistency, the healthy-user-bias critiques — serve no commercial interest, which is precisely why they get less airtime than the splashy associations. That asymmetry is the distortion this entry is written to correct: weight the confounding-aware analyses over the headline relative risks.

Sources (8)

Related entries

Erectile Dysfunction: Often the First Warning Light for Your HeartStrongRaynaud's: Usually Harmless, Sometimes a Warning, Managed by Keeping WarmModerateEnlarged Prostate (BPH): Saw Palmetto Doesn't Beat Placebo, and It's Not CancerModerateCardiovascular Health Management: Blood Pressure, Lipids, Clotting, and Heart HealthStrong
HIGHLast updated June 2026
Open in the Library: search, filter, every entry →

We set no cookies and run no ad trackers. We count visits with Cloudflare's cookieless, privacy-first analytics. The only thing stored on your device is which example you last viewed.